Advertisement

Predictors of thrombosis in testicular cancer during platinum-based chemotherapy

  • Pia Paffenholz
  • Katharina Grein
  • Isabel Heidegger
  • Tim Nestler
  • Markus Grabbert
  • Johannes Salem
  • Martin Hellmich
  • David Pfister
  • Axel HeidenreichEmail author
Original Article
  • 45 Downloads

Abstract

Purpose

To identify potential risk factors for the development of venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy.

Methods

We performed a retrospective analysis including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. Patient and tumor characteristics of patients with and without a thromboembolic event were analyzed.

Results

49 (19%) patients experienced a venous thromboembolic event, with the majority representing pulmonary embolism and deep venous thrombosis (47%). There were no significant differences regarding the development of a venous thromboembolic event between first- and second-line regimes. Multivariate analysis showed an increased risk for a venous thromboembolic event in patients with clinical stage ≥ IIC disease (OR 2.259 [95% CI 1.105–4.618], p = 0.026), elevated serum LDH (OR 2.162 [95% CI 1.018–4.593], p = 0.045), febrile neutropenia (OR 2.973 [95% CI 1.363–6.487], p = 0.006) and central venous access (OR 3.465 [95% CI 1.068–11.243], p = 0.039). Patients suffering from a venous thromboembolic event revealed a significantly reduced overall survival (p = 0.033) during a median follow-up of 8 months [IQR 2–18].

Conclusions

19% of all patients treated by platinum-based chemotherapy due to testicular cancer suffered from a venous thromboembolic event, associated with reduced overall survival. As a result, monitoring of cancer patients at risk as well as the improvement of patients’ awareness of a thromboembolic event should thus be the main goal of their treating physicians.

Keywords

Thrombosis Germ cell tumor Cisplatin Chemotherapy 

Abbreviations

AFP

Alpha-Fetoprotein

BEP

Bleomycin, etoposide, cisplatin

GCT

Germ cell tumors

β-hCG

Human chorionic gonadotropin

IGCCCG

International germ cell cancer collaborative group

IQR

Interquartile range

LDH

Lactate dehydrogenase

PEI

Cisplatin, etopside, ifosfamide

PC-RPLND

Post-chemotherapy retroperitoneal lymph node dissection

TIP

Cisplatin, ifosfamide, paclitaxel

Notes

Authors contribution

MG: manuscript editing. KG: data collection or management, data analysis. IH: manuscript editing. AH: project development, manuscript editing, supervision. MH: data analysis, manuscript editing. TN: manuscript editing. PP: project development, data collection or management, data analysis, manuscript writing/editing. DP: project development, manuscript editing, supervision. JS: manuscript editing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Supplementary material

345_2018_2598_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Albers P, Albrecht W, Algaba F et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68:1054–1068.  https://doi.org/10.1016/j.eururo.2015.07.044 CrossRefPubMedGoogle Scholar
  2. 2.
    Donnellan E, Khorana AA (2017) Cancer and venous thromboembolic disease: a review. Oncologist 22:199–207.  https://doi.org/10.1634/theoncologist.2016-0214 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Piketty A-C, Fléchon A, Laplanche A et al (2005) The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93:909–914.  https://doi.org/10.1038/sj.bjc.6602791 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Fosså SD, Aass N, Harvei S, Tretli S (2004) Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 90:607–612.  https://doi.org/10.1038/sj.bjc.6601558 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gizzi M, Oberic L, Massard C et al (2016) Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer 69:151–157.  https://doi.org/10.1016/j.ejca.2016.10.003 CrossRefPubMedGoogle Scholar
  6. 6.
    Heidegger I, Porres D, Veek N et al (2017) Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer. Urol Int 99:104–109.  https://doi.org/10.1159/000471888 CrossRefPubMedGoogle Scholar
  7. 7.
    Dieckmann K-P, Gerl A, Witt J et al (2010) Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 21:1607–1611.  https://doi.org/10.1093/annonc/mdp597 CrossRefPubMedGoogle Scholar
  8. 8.
    Weijl NI, Rutten MFJ, Zwinderman AH et al (2000) Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18:2169–2178.  https://doi.org/10.1200/JCO.2000.18.10.2169 CrossRefPubMedGoogle Scholar
  9. 9.
    Solari L, Krönig M, Ihorst G et al (2016) High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy. Urol Int 96:399–405.  https://doi.org/10.1159/000445126 CrossRefPubMedGoogle Scholar
  10. 10.
    Bezan A, Posch F, Ploner F et al (2017) Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One 12:e0176283.  https://doi.org/10.1371/journal.pone.0176283 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mandala M, Falanga A, Roila F, ESMO Guidelines Working Group (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22:vi85–vi92.  https://doi.org/10.1093/annonc/mdr392 CrossRefPubMedGoogle Scholar
  12. 12.
    Burness CB, Perry CM (2014) Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs 74:243–262.  https://doi.org/10.1007/s40265-013-0174-4 CrossRefPubMedGoogle Scholar
  13. 13.
    Babyak MA (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 66:411–421PubMedGoogle Scholar
  14. 14.
    Moore RA, Adel N, Riedel E et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29:3466–3473.  https://doi.org/10.1200/JCO.2011.35.5669 CrossRefPubMedGoogle Scholar
  15. 15.
    Shlebak AA, Smith DB (1997) Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol 39:462–466.  https://doi.org/10.1007/s002800050599 CrossRefPubMedGoogle Scholar
  16. 16.
    Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490–493.  https://doi.org/10.1016/j.thromres.2009.12.023 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chaturvedi S, Sidana S, Elson P et al (2014) Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One 9:e94048.  https://doi.org/10.1371/journal.pone.0094048 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Honecker F, Koychev D, Luhmann AD et al (2013) Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie 36:7–7.  https://doi.org/10.1159/000355652 CrossRefGoogle Scholar
  19. 19.
    Srikanthan A, Tran B, Beausoleil M et al (2015) Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 33:582–587.  https://doi.org/10.1200/JCO.2014.58.6537 CrossRefPubMedGoogle Scholar
  20. 20.
    Mead GM, Stenning SP (1997) The international germ cell consensus classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol (R Coll Radiol) 9:207–209CrossRefGoogle Scholar
  21. 21.
    Kyriazi V, Theodoulou E (2013) Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med 137:1286–1295.  https://doi.org/10.5858/arpa.2012-0490-RA CrossRefPubMedGoogle Scholar
  22. 22.
    Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484–490.  https://doi.org/10.1200/JCO.2005.03.8877 CrossRefPubMedGoogle Scholar
  23. 23.
    Lin J, Proctor MC, Varma M et al (2003) Factors associated with recurrent venous thromboembolism in patients with malignant disease. J Vasc Surg 37:976–983.  https://doi.org/10.1067/mva.2003.191 CrossRefPubMedGoogle Scholar
  24. 24.
    Nestler T, Huber J, Laury AM et al (2018) Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries. World J Urol.  https://doi.org/10.1007/s00345-018-2222-x CrossRefPubMedGoogle Scholar
  25. 25.
    Carrier M, Lee AY (2009) Prophylactic and therapeutic anticoagulation for thrombosis—major issues in oncology. Nat Clin Pract Oncol 6:74–84.  https://doi.org/10.1038/ncponc1244 CrossRefPubMedGoogle Scholar
  26. 26.
    Yamashita Y, Wada H, Nomura H et al (2014) Elevated fibrin-related markers in patients with malignant diseases frequently associated with disseminated intravascular coagulation and venous thromboembolism. Intern Med 53:413–419CrossRefGoogle Scholar
  27. 27.
    Li XD, Guo SJ, Chen SL et al (2017) Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis. Zhonghua Wai Ke Za Zhi 55:603–607.  https://doi.org/10.3760/cma.j.issn.0529-5815.2017.08.010 CrossRefPubMedGoogle Scholar
  28. 28.
    Madoiwa S (2017) Management of venous thromboembolism in cancer patients. Gan To Kagaku Ryoho 44:2064–2071PubMedGoogle Scholar
  29. 29.
    Noble S, Prout H, Nelson A (2015) Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 9:337.  https://doi.org/10.2147/PPA.S79373 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cushman M (2007) Epidemiology and risk factors for venous thrombosis. Semin Hematol 44:62–69.  https://doi.org/10.1053/j.seminhematol.2007.02.004 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Pia Paffenholz
    • 1
    return OK on get
  • Katharina Grein
    • 1
  • Isabel Heidegger
    • 2
  • Tim Nestler
    • 1
  • Markus Grabbert
    • 1
  • Johannes Salem
    • 1
  • Martin Hellmich
    • 3
  • David Pfister
    • 1
  • Axel Heidenreich
    • 1
    Email author
  1. 1.Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic SurgeryUniversity Hospital CologneCologneGermany
  2. 2.Department of UrologyMedical University InnsbruckInnsbruckAustria
  3. 3.Institute of Medical Statistics and Computational BiologyUniversity of CologneCologneGermany

Personalised recommendations